Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/Refractory AML or BPDCN
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a clincal trial initiated by investigator to evaluate the safety and efficacy of anti-CD123 CAR-NK in the treatment of patients with relapsed/refractory acute myeloid leukemia or blastic plasma cell like dendritic cell tumors.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 18 do 75 lat
- •Potwierdzona diagnoza białaczki ostrej lub rzadkiego nowotworu komórek dendrytycznych
- •Nowotwór wykazuje obecność białka CD123
- •Pacjent jest w dobrej kondycji ogólnej (ocena ECOG 0-2)
- •Spodziewana długość życia ponad 12 tygodni
- •Prawidłowe funkcjonowanie serca, nerek i wątroby
- •Wystarczająca liczba krwinek (białe > 1,0, neutrofile > 0,5, płytki > 50)
- •Saturacja tlenu powyżej 92%
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- August 28, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology.
Wuhan, China
Trial contact
Wei Jia, Professor
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/29/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.